Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).

Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA, Govindan R, Peng G, Monberg MJ, Obasaju CK, Socinski MA.

Support Care Cancer. 2009 Mar;17(3):307-13. doi: 10.1007/s00520-008-0489-y. Epub 2008 Sep 10.

PMID:
18781341
2.

Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS).

Hollen PJ, Gralla RJ, Kris MG, Eberly SW, Cox C.

Support Care Cancer. 1999 May;7(3):140-8.

PMID:
10335932
3.

A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer.

Hollen PJ, Gralla RJ, Cox C, Eberly SW, Kris MG.

Lung Cancer. 1997 Oct;18(2):119-36.

PMID:
9316004
4.

Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.

Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ.

Chest. 2009 Jun;135(6):1588-1595. doi: 10.1378/chest.08-1430. Epub 2009 Feb 2.

PMID:
19188545
5.

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

PĂ©rol M, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim JH, Karaseva N, Yurasov S, Zimmermann A, Lee P, Carter GC, Reck M, Cappuzzo F, Garon EB.

Lung Cancer. 2016 Mar;93:95-103. doi: 10.1016/j.lungcan.2016.01.007. Epub 2016 Jan 19.

PMID:
26898621
6.
7.

A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.

Barlesi F, Chouaid C, Crequit J, Le Caer H, Pujol JL, Legodec J, Vergnenegre A, Le Treut J, Fabre-Guillevin E, Loundou A, Auquier P, Simeoni MC, Thomas PA.

Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):783-90. doi: 10.1093/icvts/ivv050. Epub 2015 Mar 11.

PMID:
25765952
8.

Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.

Zhang J, Gay HA, Russo S, Parent T, Aljumaily R, Walker PR.

Lung Cancer. 2014 Jan;83(1):67-72. doi: 10.1016/j.lungcan.2013.09.007. Epub 2013 Sep 25.

PMID:
24246506
9.

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.

Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J.

Br J Cancer. 2000 Aug;83(4):447-53.

10.

Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results from two prospective clinical trials.

Hallqvist A, Bergman B, Nyman J.

Radiother Oncol. 2012 Jul;104(1):39-44. doi: 10.1016/j.radonc.2012.05.006. Epub 2012 Jun 23.

PMID:
22727262
11.

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.

Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zielinski CC.

Lancet Oncol. 2012 Mar;13(3):292-9. doi: 10.1016/S1470-2045(11)70339-4. Epub 2012 Feb 14.

PMID:
22336221
12.

Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.

Machtay M, Lee JH, Stevenson JP, Shrager JB, Algazy KM, Treat J, Kaiser LR.

J Thorac Cardiovasc Surg. 2004 Jan;127(1):108-13.

14.
15.

Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.

Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, Roth AD, Stahel RA, Majno SB, Peters S, Jost L, Furrer M, Thierstein S, Schmid RA, Hsu-Schmitz SF, Mirimanoff RO, Ris HB, Pless M.

Lancet Oncol. 2009 Aug;10(8):785-93. doi: 10.1016/S1470-2045(09)70172-X. Epub 2009 Jul 13.

PMID:
19604722
16.

Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.

Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK.

J Thorac Oncol. 2008 Jan;3(1):37-45. doi: 10.1097/JTO.0b013e31815e5d9a.

17.

Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.

de Marinis F, Pereira JR, Fossella F, Perry MC, Reck M, Salzberg M, Jassem J, Peterson P, Liepa AM, Moore P, Gralla RJ.

J Thorac Oncol. 2008 Jan;3(1):30-6. doi: 10.1097/JTO.0b013e31815e8b48.

18.

Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.

Bunn PA Jr.

Clin Lung Cancer. 2004 Sep;6(2):85-98. Review.

PMID:
15476594
19.
20.

Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.

Abratt RP, Lee JS, Han JY, Tsai CM, Boyer M, Mok T, Kim SW, Lee JS, Brnabic AJ, Reece WH, Lehnert M.

J Thorac Oncol. 2006 Feb;1(2):135-40.

Supplemental Content

Support Center